Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized two arm phase II study to further evaluate the efficacy of fulvestrant
plus enza compared to single agent fulvestrant in postmenopausal women with locally advanced
AR+/ER+/Her2- BC who will have local surgery after ~4 months on treatment.